非酒精性脂肪性肝病的潜在新疗法

谢晓; 陆伦根

doi:10.3969/j.issn.1001-5256.2017.12.042

非酒精性脂肪性肝病的潜在新疗法

DOI: 10.3969/j.issn.1001-5256.2017.12.042

谢晓,
陆伦根

上海交通大学附属第一人民医院消化科

详细信息

中图分类号: R575.5
计量
- 文章访问数: 1592
- HTML全文浏览量: 10
- PDF下载量: 390
- 被引次数: 0
出版历程
- 收稿日期: 2017-08-07
- 出版日期: 2017-12-20

Potential therapeies for nonalcoholic fatty liver disease

Xie Xiao,
Lu LunGen

Department of Gastroenterology, The First People's Hospital Affiliated to Shanghai Jiao Tong University

摘要

摘要: 非酒精性脂肪性肝病(NAFLD)是全世界最常见的慢性肝脏疾病,其与肥胖、高脂血症、胰岛素抵抗和2型糖尿病相关。脂质的沉积、胰岛素抵抗、炎症反应均可导致NAFLD的形成,但是具体形成机制尚不明确。随着对NAFLD发病机制的深入研究,巨噬细胞、氧化应激、肠道菌群种类等均影响NAFLD的形成,相应的调控巨噬细胞的极化、抗氧化剂类胡萝卜素及抗肿瘤坏死因子的使用可以阻止或者延缓NAFLD的进程。综述了NAFLD潜在新疗法的研究进展。
- 非酒精性脂肪性肝病 /
- 治疗 /
- 综述
Abstract: Nonalcoholic fatty liver disease ( NAFLD) is one of the most common chronic liver diseases in the world, and it is associated with obesity, hyperlipidemia, insulin resistance, and type 2 diabetes. Lipid deposition, insulin resistance, and inflammatory response may induce NAFLD, but detailed mechanism remains unknown. In-depth studies on the pathogenesis of NAFLD have found that macrophage, oxidative stress, and gut microbiota have certain influence on the pathogenesis of NAFLD, and regulation of macrophage polarization and application of carotenoids and anti-tumor necrosis factor may prevent or delay the progression of NAFLD. This article reviews the research advances in potential therapies for NAFLD.
- nonalcoholic fatty liver disease /
- therapy /
- review

HTML全文

参考文献(48)

[1]CHALASANI N, YOUNOSSI Z, LAVINE JE, et al.The diagnosis and management of nonalcoholic fatty liver disease:practice guidance from the american association for the study of liver diseases[J].Hepatology, 2017.[Epub ahead of print]

[2]LOOMBA R, SANYAL AJ.The global NAFLD epidemic[J].Nat Rev Gastroenterol Hepatol, 2013, 10 (11) :686-690.

[3]ABENAVOLI L, MILIC N, di RENZO L, et al.Metabolic aspects of adult patients with nonalcoholic fatty liver disease[J].World JGastroenterol, 2016, 22 (31) :7006-7016.

[4]BUZZETTI E, PINZANI M, TSOCHATZIS EA.The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD) [J].Metabolism, 2016, 65 (8) :1038-1048.

[5]HAAS JT, FRANCQUE S, STAELS B, et al.Pathophysiology and mechanisms of nonalcoholic fatty liver disease[J].Annu Rev Physiol, 2016, 78:181-205.

[6]LOOMBA R, ABRAHAM M, UNALP A, et al.Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis[J].Hepatology, 2012, 56 (3) :943-951.

[7]POLYZOS SA, KOUNTOURAS J, MANTZOROS CS.Adipokines in nonalcoholic fatty liver disease[J].Metabolism, 2016, 65 (8) :1062-1079.

[8]GULCELIK NE, HALIL M, ARIOGUL S, et al.Adipocytokines and aging:adiponectin and leptin[J].Minerva Endocrinol, 2013, 38 (2) :203-210.

[9]BERTOLANI C, MARRA F.The role of adipokines in liver fibrosis[J].Pathophysiology, 2008, 15 (2) :91-101.

[10]SINGH R, KAUSHIK S, WANG Y, et al.Autophagy regulates lipid metabolism[J].Nature, 2009, 458:1131-1135.

[11]ROLO AP, TEODORO JS, PALMEIRA CM.Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis[J].Free Radic Biol Med, 2012, 52 (1) :59-69.

[12]GUSDON AM, SONG KX, QU S.Nonalcoholic Fatty liver disease:pathogenesis and therapeutics from a mitochondria-centric perspective[J].Oxid Med Cell Longev, 2014, 2014:637027.

[13]FERRAMOSCA A, di GIACOMO M, ZARA V.et al.Antioxidant dietary approach in treatment of fatty liver:new insights and updates[J].World J Gastroenterol, 2017, 23 (23) :4146-4157.

[14]SPAHIS S, DELVIN E, BORYS JM, et al.Oxidative stress as a critical factor in nonalcoholic fatty liver disease pathogenesis[J].Antioxid Redox Signal, 2017, 26 (10) :519-541.

[15]TAKAKI A, KAWAI D, YAMAMOTO K.Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH) [J].Int J Mol Sci, 2013, 14 (10) :20704-20728.

[16]DIXON LJ, BARNES M, TANG H, et al.Kupffer cells in the liver[J].Compr Physiol, 2013, 3 (2) :785-797.

[17]SICA A, INVERNIZZI P, MANTOVANI A.Macrophage plasticity and polarization in liver homeostasis and pathology[J].Hepatology, 2014, 59 (5) :2034-2042.

[18]QUIGLEY EM, ABU-SHANAB A, MURPHY EF, et al.The metabolic role of the microbiome:implications for nafld and the metabolic syndrome[J].Semin Liver Dis, 2016, 36 (4) :312-316.

[19]DOULBERIS M, KOTRONIS G, GIALAMPRINOU D, et al.Non-alcoholic fatty liver disease:an update with special focus on the role of gut microbiota[J].Metabolism, 2017, 71:182-197.

[20]HE X, JI G, JIA W, et al.Gut microbiota and nonalcoholic fatty liver disease:insights on mechanism and application of metabolomics[J].Int J Mol Sci, 2016, 17 (3) :300.

[21]LEY RE, BCKHED F, TURNBAUGH P, et al.Obesity alters gut microbial ecology[J].Proc Natl Acad Sci U S A, 2005, 102 (31) :11070-11075.

[22]de FILIPPO C, CAVALIERI D, di PAOLA M, et al.Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa[J].Proc Natl Acad Sci U S A, 2010, 107 (33) :14691-14696.

[23]CHANG HC, GUARENTE L.SIRT1 and other sirtuins in metabolism[J].Trends Endocrinol Metab, 2014, 25 (3) :138-145.

[24]NASSIR F, IBDAH JA.et al.Sirtuins and nonalcoholic fatty liver disease[J].World J Gastroenterol, 2016, 22 (46) :10084-10092.

[25]DING RB, BAO J, DENG CX, et al.Emerging roles of SIRT1 in fatty liver diseases[J].Int J Biol Sci, 2017, 13 (7) :852-867.

[26]TOBITA T, GUZMAN-LEPE J, TAKEISHI K.et al.SIRT1 disruption in human fetal hepatocytes leads to increased accumulation of glucose and lipids[J].PLo S One, 2016, 11 (2) :e0149344.

[27]COLAK Y, YESIL A, MUTLU HH, et al.A potential treatment of non-alcoholic fatty liver disease with SIRT1 activators[J].J Gastrointestin Liver Dis, 2014, 23 (3) :311-319.

[28]YILMAZ B, SAHIN K, BILEN H, et al.Carotenoids and non-alcoholic fatty liver disease[J].Hepatobiliary Surg Nutr, 2015, 4 (3) :161-171.

[29]OSEINI AM, SANYAL AJ.et al.Therapies in non-alcoholic steatohepatitis (NASH) [J].Liver Int, 2017, 37 (Suppl 1) :97-103.

[30]NI Y, NAGASHIMADA M, ZHUGE F, et al.Astaxanthin prevents and reverses diet-induced insulin resistance and steatohepatitis in mice:a comparison with vitamin E[J].Sci Rep, 2015, 5:17192.

[31]CASTENMILLER JJ, WEST CE.Bioavailability and bioconversion of carotenoids[J].Annu Rev Nutr, 1998, 18:19-38.

[32]BURRI BJ, LA FRANO MR, ZHU C.Absorption, metabolism, and functions ofβ-cryptoxanthin[J].Nutr Rev, 2016, 74 (2) :69-82.

[33]HAEGELE AD, GILLETTE C, O'NEILL C, et al.Plasma xanthophyll carotenoids correlate inversely with indices of oxidative DNAdamage and lipid peroxidation[J].Cancer Epidemiol Biomarkers Prev, 2000, 9 (4) :421-425.

[34]SUGIURA M, NAKAMURA M, OGAWA K, et al.High serum carotenoids associated with lower risk for the metabolic syndrome and its components among Japanese subjects:Mikkabi cohort study[J].Br J Nutr, 2015, 114 (10) :1674-1682.

[35]KATSUURA S, IMAMURA T, BANDO N, et al.beta-Carotene and beta-cryptoxanthin but not lutein evoke redox and immune changes in RAW264 murine macrophages[J].Mol Nutr Food Res, 2009, 53 (11) :1396-1405.

[36]TAKAYANAGI K.Prevention of adiposity by the oral administration ofβ-cryptoxanthin[J].Front Neurol, 2011, 2:67.

[37]KOBORI M, NI Y, TAKAHASHI Y, et al.β-Cryptoxanthin alleviates diet-induced nonalcoholic steatohepatitis by suppressing inflammatory gene expression in mice[J].PLo S One, 2014, 9 (5) :e98294.

[38]CHEN JT, KOTANI K.Astaxanthin as a potential protector of liver function:a review[J].J Clin Med Res, 2016, 8 (10) :701-704.

[39]YANG Y, BAE M, KIM B.Astaxanthin prevents and reverses the activation of mouse primary hepatic stellate cells[J].J Nutr Biochem, 2016, 29:21-26.

[40]KOBORI M, TAKAHASHI Y, SAKURAI M, et al.Hepatic transcriptome profiles of mice with diet-induced nonalcoholic steatohepatitis treated with astaxanthin and vitamin E[J].Int J Mol Sci, 2017, 18 (3) :e593.

[41] FERRAMOSCA A, di GIACOMO M, ZARA V.Antioxidant dietary approach in treatment of fatty liver:new insights and updates[J].World J Gastroenterol, 2017, 23 (23) :4146-4157.

[42]LISBOA QC, COSTA SM, COUTO CA.Current management of non-alcoholic fatty liver disease[J].Rev Assoc Med Bras, 2016, 2 (9) :872-878.

[43]TAKAHASHI Y, SUGIMOTO K, INUI H, et al.Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J].World J Gastroenterol, 2015, 21 (13) :3777-3785.

[44]ZENG T, ZHANG CL, ZHAO XL, et al.Pentoxifylline for the treatment of nonalcoholic fatty liver disease:a meta-analysis of randomized double-blind, placebo-controlled studies[J].Eur JGastroenterol Hepatol, 2014, 26 (6) :646-653.

[45]DU J, MA YY, YU CH, et al.Effects of pentoxifylline on nonalcoholic fatty liver disease:A meta-analysis[J].World J Gastroenterol, 2014, 20 (2) :569-577.

[46]KANURI G, LANDMANN M, PRIEBS J, et al.Moderate alcohol consumption diminishes the development of non-alcoholic fatty liver disease (NAFLD) in ob/ob mice[J].Eur J Nutr, 2016, 55 (3) :1153-1164.

[47]FAGHIHZADEH F, ADIBI P, HEKMATDOOST A.The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease:a randomised, doubleblind, placebo-controlled study[J].Br J Nutr, 2015, 114 (5) :796-803.

[48]ELGEBALY A, RADWAN IA, ABOELNAS MM, et al.Resveratrol supplementation in patients with non-alcoholic fatty liver disease:systematic review and meta-analysis[J].J Gastrointestin Liver Dis, 2017, 26 (1) :59-67.

施引文献

资源附件(0)

访问统计